Screening of synthetic 1,2,3-triazolic compounds inspired by SRPIN340 as anti-Trypanosoma cruzi agents

ABSTRACT

Background:

The current treatments for Chagas disease (CD) include benznidazole and nifurtimox, which have limited efficacy and cause numerous side effects. Triazoles are candidates for new CD treatments due to their ability to eliminate T. cruzi parasites by inhibiting ergosterol synthesis, thereby damaging the cell membranes of the parasite.

Methods:

Eleven synthetic analogs of the kinase inhibitor SRPIN340 containing a triazole core (compounds 6A-6K) were screened in vitro against the Tulahuen strain transfected with β-galactosidase, and their IC50, CC50, and selectivity indexes (SI) were calculated. Compounds with an SI > 50 were further evaluated in mice infected with the T. cruzi Y strain by rapid testing.

Results:

Eight compounds were active in vitro with IC50 values ranging from 0.5-10.5 µg/mL. The most active compounds, 6E and 6H, had SI values of 125.2 and 69.6, respectively. These compounds also showed in vivo activity, leading to a reduction in parasitemia at doses of 10, 50, and 250 mg/kg/day. At doses of 50 and 250 mg/kg/day, parasitemia was significantly reduced compared to infected untreated animals, with no significant differences between the effects of 6E and 6H.

Conclusions:

This study identified two new promising compounds for CD chemotherapy and confirmed their activity against T. cruzi.

Keywords:
Chagas disease; Triazoles; Screening; Chemotherapy

INTRODUCTION

Chagas disease (CD), caused by the obligate hemoflagellate protozoan parasite Trypanosoma cruzi, was first identified over a century ago¹. Transmission of CD occurs through various routes, including vector-borne transmission via blood-sucking triatomine insects, ingestion of contaminated food, blood transfusion, organ transplantation, and congenital transmission². The disease is endemic to 21 countries, primarily in Latin America³, affecting approximately six million people. However, CD has extended its reach to several countries across different continents due to the migration of infected individuals, leading to transmission mechanisms independent of triatomine vectors^4,5. CD typically manifests in an initial acute phase, progressing into an asymptomatic chronic phase for survivors of the acute stage. Approximately 30-35% of chronically infected individuals develop cardiac or digestive alterations, such as megaesophagus and megacolon⁶. Furthermore, disease reactivation in chronically infected patients often occurs in immunodeficient states, such as those induced by transplantation⁷, lupus^8,9, and HIV infections¹⁰. The reactivation of CD in HIV-infected patients poses particular challenges, with an estimated 16,100 reported cases, comprising approximately 1.3-5% of patients living with T. cruzi infection¹¹. This subset of patients commonly exhibits more severe clinical manifestations, including central nervous system involvement^10,12.

Since its discovery, there have been persistent efforts to find effective treatments for all clinical stages of CD, particularly late chronic infections, which pose significant challenges. Benznidazole (BZ) and nifurtimox (NF) are currently the only drugs available for CD treatment in humans¹³. While both drugs achieve a significant cure rate in acute cases and recent infections, they are associated with numerous side effects, leading to treatment discontinuation, especially in adults¹⁴. Additionally, low cure rates have been reported in the later chronic phase¹⁴, including immunosuppressed patients who may experience reactivation and severe clinical features¹⁵. Consequently, ongoing research focuses on identifying better treatment options, including drug repositioning¹⁶, exploration of natural products¹⁷, and the development of new drugs¹⁸ targeting specific T. cruzi biomolecular targets.

In recent years, several clinical trials have investigated modifications to the benznidazole (BZ) regimen, including BENDITA¹⁹, MULTIBENZ²⁰, and BETTY²¹. While numerous drugs targeting Trypanosoma cruzi have undergone preclinical testing^22,23, only a limited number have progressed to human trials. Notably, fexinidazole, a re-evaluated molecule licensed for Human American trypanosomiasis, underwent assessment of its risk-benefit profile for treating adult patients in the chronic phase of Chagas disease¹⁹. Among the various classes of compounds that target T. cruzi, 1,2,3-triazoles have emerged as significant^17-20, including itraconazole²⁴, posaconazole²⁵, and the prodrug ravuconazole (E1224)²⁶, which have progressed to clinical trials. The inclusion of 1,2,3-triazoles in clinical trials and their relevance in Chagas disease (CD) treatment studies appear to stem from their primary mechanism of action, which involves inhibiting the 14α-sterol-demethylase enzyme, thereby preventing ergosterol binding²⁷ and ultimately leading to the fatal disruption of the parasite membrane.

In Brazil, reports on azole derivatives have shown inconsistency. While one clinical study demonstrated the efficacy of azoles, including itraconazole and ketoconazole, in reducing parasitemia, particularly in cases of CD reactivation in immunosuppressed patients with HIV²⁸, other study²⁹ reported failure when evaluating itraconazole as an alternative for chronically infected patients. Despite this variability, both approaches share the common goal of substituting benznidazole due to its adverse effects. In contrast, in Chile, the clinical experience with itraconazole and allopurinol in patients with the chronic phase of CD is more promising, with their use leading to parasitological cure in patients treated with itraconazole^24,30. Additionally, there are reports of posaconazole successfully treating Chagas Disease reactivation in a patient with comorbid systemic lupus erythematosus³¹.

Azoles continue to be investigated in studies exploring their combinations with BZ, such as posaconazole in the STOPCHAGAS clinical trials³² and fosravuconazole in the BENDITA trial³³.

Considering the relevance of azoles in the pursuit of new active drugs against CD, this study evaluated the in vitro and in vivo anti-T. cruzi activity of 11 synthetic 1,2,3-triazole compounds inspired by the kinase inhibitor SRPIN340, which inhibits glioblastoma proliferation in vitro³⁴.

METHODS

● Substances

The compounds 6A-6K were evaluated as anti-T. cruzi agents, were prepared and structurally characterized as previously described by Sousa et al. Their structures are depicted in Figure 1.

In comparison to BZ (Figure 1), a compound clinically utilized for treating Chagas' Disease, compounds 6A-6K feature a tri-substituted aromatic ring (highlighted in blue in Figure 1), while BZ presents a monosubstituted one. Additionally, BZ possesses an amide substituent (highlighted in red in Figure 1), whereas compounds 6A-6K feature a 1,2,3-triazole functionality (highlighted in green in Figure 1). Notably, the 1,2,3-triazole group acts as a bioisostere of an amide functionality. Although both BZ and compounds 6A-6K fall under the category of azoles, the former is an imidazole, whereas the latter are 1,2,3-triazoles. 1,2,3-Triazoles constitute a class of five-membered ring heterocyclic compounds widely utilized in medicinal chemistry. They possess the ability to form hydrogen bonds and participate in dipole-dipole and pi-stacking interactions, thus enhancing solubility and binding affinity to molecular targets. Furthermore, this structural framework typically exhibits resistance to acidic and basic hydrolysis under oxidizing and reducing conditions³⁵. Due to these advantages, the 1,2,3-triazole structural motif has been extensively employed in designing compounds with various biological activities^35-38, including trypanocidal agents^39-42. Compounds 6A-6K were synthesized to assess the influence of diverse groups attached to the aromatic ring (highlighted in blue in Figure 1) and the 1,2,3-triazole functionality on bioactivity.

FIGURE 1:
Structures of benznidazole and 1,2,3-triazole compounds evaluated against Trypanosoma cruzi in the screening assays.

● Anti-T. cruzi evaluation in vitro

The in vitro assays were conducted at the Centro de Pesquisas René Rachou-Fiocruz (FIOCRUZ-MINAS), Minas Gerais, Brazil. To evaluate trypanocidal activity, initial in vitro screening was performed following the protocols described by Buckner et al.⁴³ and Romanha et al.⁴⁴. In this assay, Tulahuen T. cruzi strain expressing β-galactosidase trypomastigotes and intracellular amastigotes were cultured in mouse L929 fibroblasts in RPMI1640 medium without phenol red and containing 10% fetal bovine serum. Tissue culture microplates with L929 fibroblasts were incubated overnight at 37°C with 5% CO₂. Subsequently, the Tulahuen β-galactosidase-expressing trypomastigotes were added at a ratio of 1:10 cells to trypomastigotes for 2 hours. The medium was then replaced with fresh medium, and the cultures were incubated for 48 hours. Following this step, the medium was replaced with a solution of the test compound, diluted in dimethyl sulfoxide (DMSO, less than 1%), in RPMI1640 medium with concentrations ranging from 5 to 20 µM. After seven days of incubation, a solution containing 100 µM chlorophenol red β-D-galactopyranoside and 0.1% Nonidet P-40 was added and incubated overnight, after which absorbance was assessed at 570 nm. Benznidazole was utilized as a positive control at 1 µg/mL (3.84 µM).

Because the amount of beta-galactosidase is directly proportional to the number of parasites, trypanocidal activity was assessed by measuring the decrease in beta-galactosidase activity in the treated cultures compared to the infected control culture without treatment. To determine the cytotoxicity of the compounds on L929 cells, absorbance was measured at two wavelengths (570 and 600 nm) after 4-6 hours of incubation with alamarBlue® reagent (Invitrogen Corporation, USA). Cytotoxicity was evaluated by analyzing the difference in reagent reduction between treated cells (TC) and untreated cells (UT) using an equation provided by the manufacturer of alamarBlue®:

$\begin{array}{rr}& \left(\mathrm{117,216}\right)\text{(Abs570 TC) -}\left(\mathrm{80,586}\right)\text{(Abs600 TC) X}100\\ & \left(\mathrm{117,216}\right)\text{(Abs570 UT) - (80,586) (Abs600 UT)}\end{array}$

Half-maximum inhibitory concentration (IC50) and half-maximum cytotoxicity concentration (CC50) values were determined through linear interpolation⁴⁵ using Excel software (Microsoft Corporation, USA). The assay was conducted in triplicate, and the results are expressed as the percentage inhibition of parasite growth Cytotoxicity assay.

In vitro cytotoxicity assessments of the compounds were performed using AlamarBlue®. The cells and experimental conditions mirrored those used for the trypanocidal assay. After a 96-hour exposure of mouse L929 fibroblasts infected with T. cruzi to the test compounds, alamarBlue® was added, and absorbance was measured after an additional 4-6-hour incubation. IC50 values were determined by linear interpolation, and the selectivity index (SI) was calculated as the ratio of CC50 (the concentration causing 50% cytotoxicity) to IC50 (the concentration causing 50% parasitic inhibition). Benznidazole served as the positive control for comparative analysis.

● Anti-T. cruzi evaluation in vivo

The in vivo assays were conducted at the Laboratório de Pesquisas Clínicas, Escola de Farmácia, Universidade Federal de Ouro Preto (UFOP), Minas Gerais State, Brazil, utilizing only compounds with a selectivity index (SI) exceeding 50 (Table 1).

TABLE 1:
Trypanocidal activity, cytotoxicity, and selectivity index (SI) of 1,2,3-triazole compounds 6A-K and benznidazole.

Compound	IC50 µg/mL (µM)	CC50 µg/mL (µM)	SI
6A	Not active	-	-
6B	2.3 (5.0)	36.1 (79)	15.7
6C	3.4 (6.8)	80.0 (161.3)	23.5
6D	6.6 (15.7)	>20.0 (47.6)	>3.0
6E	0.5 (1.3)	62.6 (160)	125.2
6F	Not active	-	-
6G	4.7 (10.4)	>160 (355)	34.0
6H	2.3 (4.6)	>160 (323)	69.6
6I	Not active	-	-
6J	6.5 (15.6)	>20.0 (48)	6.9
6K	10.5 (23.5)	>20.0 (45)	3.1
Benznidazole	1.0 (3.81)	625 (2381)	625

• IC₅₀: Inhibitory concentration at 50% of intracellular amastigotes of Trypanosoma cruzi Tulahuen transfected with β-galactosidase strain growth inhibition; CC ₅₀ : cytotoxic concentration at 50% cell viability of mice fibroblast L929. Selectivity index: CC₅₀/IC₅₀. The assayed concentrations were constrained by the compound's solubility in the culture medium, spanning from 20 to 160 µg/mL; (-): not determined.

Swiss female mice aged 28-30 days were obtained from the Centro de Ciência Animal of the Universidade Federal de Ouro Preto (UFOP), Minas Gerais State, Brazil. The animals were housed in a temperature range of 20-24 °C with a 12-hour light-dark cycle, and had ad libitum access to filtered water and commercial feed. The experimental procedures were approved by the institutional Comitê de Ética em Experimentação Animal (CEUA-UFOP), Minas Gerais State, Brazil, Protocol 2157041219.

The mice were intraperitoneally infected with 1x10⁴ blood trypomastigotes of the T. cruzi Y strain obtained from mice maintained by successive blood passages (CEUA 2015/50). Infection was confirmed by fresh blood examination (FBE)⁴⁶ on the 4^th day after infection, and treatment commenced. For the in vivo test, the highest concentration attainable when blending the test compounds in various orally safe vehicles was selected. Canola oil yielded the most favorable results. The compounds were diluted with canola oil to the highest possible concentration of 25 mg/mL. Subsequently, two different dilutions (5x) were prepared, resulting in doses of 250, 50, and 10 mg/kg/day. These doses were administered via oral gavage once daily (group n = 8). In parallel, a control group of mice remained infected and untreated (INT), while another group received treatment with the reference drug (BZ) at a dose of 100 mg/kg. The BZ tablets were crushed with 0.5% gum arabic, and suspended in distilled water⁴⁷.

To evaluate the effectiveness of the compounds in reducing parasitemia, FBE was conducted daily for five consecutive days, during which parasitemia was counted⁴⁶.

RESULTS

● In vitro biological assays

The findings illustrated in Figure 2 highlight that 8 out of the 11 tested compounds demonstrated significant activity against the proliferative stages of T. cruzi. The IC50 values of these compounds ranged from 0.5 to 10.47 µg/mL.

FIGURE 2:
In vitro trypanocidal activity evaluation of active 1,2,3-triazole compounds against amastigotes of Trypanosoma cruzi Tulahuen transfected with β-galactosidase strain after 96 hours of exposition.

Compound 6E exhibited the lowest calculated IC₅₀ value (0.50 μg/mL or 1.3 µM), indicating it was twice as potent as BZ in terms of mass concentration, which exhibited an IC₅₀ of 1 µg/mL (3.81 µM). Additionally, compounds 6B, 6C, 6G, and 6H showed IC₅₀ values below 5 µg/mL (as indicated in Table 1). To ensure safety, cytotoxicity assessments were conducted for all active compounds. Compounds 6G and 6H exhibited the highest CC₅₀ values, surpassing 160 µg/mL (355 and 323 µM, respectively), with the exact value unknown due to the limited solubility of the compounds in the cell culture media. Importantly, none of the compounds demonstrated greater cytotoxicity than BZ, which had a CC₅₀ of 625 µg/mL (2.381 µM).

The selectivity index (SI), calculated as CC50/IC50, was determined for all active compounds. Compounds with SI values exceeding 50 were identified as promising candidates for in vivo experiments, following the guidelines outlined by Romanha et al.⁴⁴ Consequently, compounds 6E and 6H, with SI values of 125.2 and 69.6, respectively, were selected for further assessment.

● In vivo assay

Examination of the parasitemia curve depicted in Figure 3 revealed that compounds 6E and 6H effectively reduced the parasite count in the bloodstream of mice at doses of 10, 50, and 250 mg/kg/day.

FIGURE 3:
Parasitemia curves of Swiss mice infection with Trypanosoma cruzi Y strain treated orally with the compounds 6E, 6H, and benznidazole for five consecutive days at acute phase of infection.

Notably, the reduction was most pronounced at higher doses compared to untreated animals. Importantly, no discernible differences were observed in the effectiveness of the two compounds.

DISCUSSION

Since the discovery of Chagas disease (CD) by Chagas in 1909, finding an effective cure for all stages of the disease, particularly the late chronic phase, has posed a persistent challenge. Benznidazole has been the primary treatment option since its introduction in the 1970s. Various factors contribute to the difficulty of eradicating the parasite from the host, including the natural resistance of T. cruzi strains to existing drugs⁴⁸, the balance of host immunity, nutritional status, comorbidities, the profile of the active drug⁴⁹, and the treatment regimen^14,50.

Benznidazole treatment is effective during the acute phase of CD. However, diagnosis during this phase is often challenging due to underdiagnosis, as clinical suspicion is not always confirmed by laboratory tests^51,52. In the chronic phase, while benznidazole can improve a patient's quality of life, complete remission of infection is rarely achieved. Moreover, treatment regimens are frequently interrupted due to side effects, which can include dermatitis, fever, lymphadenopathy, bone marrow depression, thrombocytopenic purpura, and polyneuropathy¹⁴. These adverse effects are particularly relevant in cases of disease reactivation, where patients typically present with compromised health states due to immunocompromised conditions and comorbidities^9,10,53.

The demand for novel drug options for CD arises from the need to address the diverse physiological and health profiles of patients, as well as the various phases and manifestations of the disease. It is crucial to explore safer treatment alternatives, whether aimed at complete eradication of the infection or management and control, to enhance the overall health status of patients.

Therefore, addressing CD requires multiple approaches and strategies. One promising strategy involves exploring specific metabolic interactions between the parasite and host, leading to the evaluation of various compounds under experimental conditions. Among these, inhibitors of the ergosterol pathway have shown promise, including commercially available antifungal drugs such as ketoconazole, fluconazole, and itraconazole⁵⁴. More recently, triazoles, such as ravuconazole (Bristol-Myers Squibb), known for their potent antifungal properties, have demonstrated comparable or superior results to other options such as posaconazole⁵⁵.

In Brazil, clinical experience with immunocompromised patients has demonstrated the successful use of itraconazole and ketoconazole²⁸ effectively reducing parasitemia when benznidazole is not tolerated by patients. Conversely, in Chile, treatment with itraconazole and allopurinol^24,56 has led to significant reductions in parasitological test positivity and improvements or prevention of electrocardiographic abnormalities in humans, as reported by Apt et al.^24,30. In contrast, Brener et al.⁵⁷, Lauria-Pires et al.⁵⁸ and Moreira et al.²⁹ have shown that ketoconazole, ketoconazole⁵⁷, allopurinol⁵², and itraconazole²⁹ are ineffective in eradicating infection in humans. This controversy may stem from differences in individual patient characteristics, including the presence of comorbidities such as HIV^11,28 interplay between drug efficacy and the immune system⁵⁹. Variations in drug dosage and disease phase also play a role. For instance, itraconazole administered at a dose of 400 mg/day for 90 days resulted in parasitemia reduction in CD reactivation cases in patients with HIV, as demonstrated by Almeida et al²⁸. However, Moreira et al.²⁹ reported treatment failure at lower doses (100 and 200 mg/day for 90 days) in chronic patients. Furthermore, disparities in experience between Brazil and Chile may be attributed to variations in the distribution of T. cruzi discrete typing units (DTU)⁶⁰. This variation can influence treatment resistance or susceptibility, as different DTUs may respond differently to the same treatment regimens⁶¹.

In our study, the majority of the tested 1,2,3-triazoles (8 out of 11) demonstrated activity against T. cruzi in vitro. Two compounds, 6E (IC₅₀=0.5 µg/mL or 1.3 µM) and 6H (IC₅₀= 2.3 µg/mL or 4.6 µM), stood out for their anti-T. cruzi activity and selectivity were further evaluated in vivo.

Examination of the structures of the compounds investigated (Figure 1) and the results shown in Table 1 revealed that the presence of a 2-methylisoindoline-1,3-dione fragment attached to the 1,2,3-triazole ring (as seen in compounds 6A and 6I) and aliphatic groups connected to nitrogen (6F) did not contribute positively to their trypanocidal activity, as these compounds were found to be inactive. In contrast, the active compounds (6B-6E) share a common structural feature characterized by the presence of morpholine and benzyloxymethyl fragments. Furthermore, the addition of an electron-donating methoxy group at the benzyloxy ring para position resulted in reduced anti-T. cruzi activity compared with compounds featuring electron-withdrawing chlorine and bromine groups. In compounds 6B and 6C, the presence of a more electronegative chlorine atom, rather than bromine, confers greater potency against T. cruzi. Notably, 6E, one of the most active compounds, contained no substituents in the benzyloxy group.

Active substances containing piperidine fragments (6G, 6H, 6J, and 6K) exhibited a different trend compared to compounds with morpholine fragments. For instance, compound 6H, with a para-bromine atom attached to its benzyloxy functionality, showed enhanced trypanocidal activity compared to its chlorine counterpart. Interestingly, 6G, featuring an unsubstituted benzyloxy group, was not the most active compound among those with piperidine fragments.

A notable observation was that the presence of a para-methoxy group in the benzyloxy moiety resulted in the compounds with the lowest activity in each series.

In terms of cytotoxicity, our investigation revealed that compounds with a morpholine group exhibited higher toxicity compared to those with a piperidine group. The impact on cell viability varied when these compounds were applied to different cellular lineages and disease models. Notably, the cytotoxicity observed for compound 6A on L929 cells differed from its effect on the U87MG lineage, where there was no perceived cytotoxicity and cellular viability even showed an increase³⁴. Extending our analysis to other compounds examined by Sousa et al.³⁴, namely 6B to 6K (identified by Sousa et al.³⁴ as compounds 8 to 17), we found that these compounds did not substantially affect cellular growth of the U87MG lineage. This discrepancy in cytotoxicity can be primarily attributed to the choice of cell lineage, with U87MG cells representing human glioblastoma cells and L929 cells representing mouse fibroblasts. Given that L929 is a standard cell line for T. cruzi screening activity⁶², we opted to use the same uninfected cell line to assess cell viability.

Surprisingly, the in vivo study did not reflect the in vitro differences in the trypanocidal activities of the compounds, illustrating the challenge of translational studies⁶³. The molecular distinctions between the two studied compounds (6E, SI = 101; 6H, SI = 69) did not significantly affect parasitemia in the animals. Except for the smallest dose tested in vivo (10 mg/kg/day) of 6E and 6H, which did not markedly reduce parasitemia compared to the untreated group, both compounds appeared to exert their activities independently of the dose, as increasing the dose from 50 to 250 mg/kg/day did not result in improved infection control. Compared with BZ, both compounds exhibited inferior overall performance in vivo. However, combination therapy with an active agent that targets the trypomastigote form may lead to improved outcomes in mouse models. These compounds, evaluated in vivo, did not demonstrate robust trypanocidal activity during the acute phase of CD and have the potential to augment chronic treatments. Notably, screening outcomes indicated that compounds 6E and 6H exhibited substantial activity against the amastigote form, which is prevalent during the chronic stage of the disease.

Moreover, these compounds have potential applications beyond CD. Triazoles, in general, exhibit diverse biological activities, including antibacterial and antifungal properties, as well as, as explored by Sousa et al.³⁴, potential anticancer effects. This versatility underscores the broad applicability and potential therapeutic implications of the studied compounds.

In summary, this study highlighted the continued relevance of triazoles in T. cruzi drug discovery and identified two promising new compounds for CD chemotherapy research. These potential drug candidates warrant further investigation to assess their effect on the control or cure of T. cruzi infection in long-term efficacy studies, in which the compounds, infections, and outcomes would be better monitored.

ACKNOWLEDGMENTS

We are grateful to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Financiadora de Estudos e Projetos (Finep) process 0367/18 and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) for financing part of the study with the student’s fellowships. Lana M. and Mosqueira V.F. are researcher fellows from CNPq.

REFERENCES

• ¹
  Chagas C. Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem. Mem Inst Oswaldo Cruz. 1909;1(2):159-218.
• ²
  Coura JR. Chagas disease: What is known and what is needed - A background article. Mem Inst Oswaldo Cruz. 2007;102(suppl.1):113-22.
• ³
  PAHO. Chagas fact sheet 2022.
• ⁴
  Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop. 2010;115(1):14-21.
• ⁵
  Coura JR, Viñas PA, Junqueira ACV. Ecoepidemiology, Short history and control of chagas disease in the endemic countries and the new challenge for non-endemic countries. Mem Inst Oswaldo Cruz. 2014;109(7):856-62.
• ⁶
  Rassi A, Rassi A, Marin-Neto JA. Chagas disease. The Lancet. 2010;375(9723):1388-402.
• ⁷
  Da Consolação Vieira Moreira M, Cunha-Melo JR. Chagas disease infection reactivation after heart transplant. Trop Med Infec Dis. 2020;5(3):106.
• ⁸
  Burgos LG, Ortiz BDM, Canese A, Ojeda A, Melo M. Reactivation of chagas disease by immunosuppressive therapy in a patient with systemic lupus erythematosus: Report of an exceptional case. Am J Dermatopathol. 2012;34(6):e84-9.
• ⁹
  Dos Santos-Neto LL, Polcheira MF, Castro C, Corrêa Lima RA, Kozak Simaan C, Corrêa-Lima FA. Trypanosoma cruzi high parasitemia in patient with systemic lupus erythematosus. Rev Soc Bras Med Trop. 2003;36(5):613-5.
• ¹⁰
  Del Castillo M, Mendoza G, Oviedo J, Perez Bianco RP, Anselmo AE, Silva M. AIDS and chagas’ disease with central nervous system tumor-like lesion. Am J Med. 1990;88(6):693-4.
• ¹¹
  Hasslocher-Moreno AM, de Sousa AS, Xavier SS, Mendes F de SNS, Nunes EP, Grinsztejn BGJ, et al. Epidemiological-clinical profile and mortality in patientcoinfected with Trypanosoma cruzi/HIV: experience from a Brazilian reference center. Rev Soc Bras Med Trop. 2022;55:e0240-2022.
• ¹²
  Cordova E, Boschi A, Ambrosioni J, Cudos C, Corti M. Reactivation of Chagas disease with central nervous system involvement in HIV-infected patients in Argentina, 1992-2007. Int J Infect Dis. 2008;12(6):587-92.
• ¹³
  World Health Organization (WHO). Chagas disease (also known as American trypanosomiasis). Geneva: WHO; 2022.
• ¹⁴
  Coura JR, De Castro SL. A Critical Review on Chagas Disease Chemotherapy. Mem Inst Oswaldo Cruz. 2002;97(1):3-24.
• ¹⁵
  Jesú S Pinazo M, Espinosa G, Cortes-Lletget C, De Jesú S Posada E, Aldasoro E, Oliveira IS, et al. Immunosuppression and Chagas Disease: A Management Challenge. PLoS Negl Trop Dis. 2013;7(1):e1965.
• ¹⁶
  Bellera C, Sbaraglini M, Balcazar D, Fraccaroli L, Vanrell M, Casassa A, et al. High-throughput drug repositioning for the discovery of new treatments for Chagas disease. Mini Rev Med Chem. 2015;15(3):182-93.
• ¹⁷
  Apt W. Current and developing therapeutic agents in the treatment of Chagas disease. Drug Des Devel Ther. 2010;4:243-53.
• ¹⁸
  Silva ACC, Brelaz-De-Castro MCA, Lima Leite AC, Alves Pereira VR, Hernandes MZ. Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains. Front Pharmacol. 2019;10:873.
• ¹⁹
  Torrico F, Gascón J, Ortiz L, Pinto J, Rojas G, Palacios A, et al. A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease. Clin Infect Dis. 2022;76(3):1186-94.
• ²⁰
  Molina-Morant D, Fernández ML, Bosch-Nicolau P, Sulleiro E, Bangher M, Salvador F, et al. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II superiority clinical trial. Trials. 2020;21(1):328
• ²¹
  Cafferata ML, Toscani MA, Althabe F, Belizán JM, Bergel E, Berrueta M, et al. Short-course Benznidazole treatment to reduce Trypanosoma cruzi parasitic load in women of reproductive age (BETTY): a non-inferiority randomized controlled trial study protocol. Reprod Health. 2020;17(1):128
• ²²
  Bahia MT, De Figueiredo Diniz LDF, Mosqueira VCF. Therapeutical approaches under investigation for treatment of Chagas disease. Expert Opin Investig Drugs. 2014;23(9):1225-37.
• ²³
  Mazzeti AL, Capelari-Oliveira P, Bahia MT, Mosqueira VCF. Review on experimental treatment strategies against Trypanosoma cruzi J Exp Pharmacol. 2021;13:409-32.
• ²⁴
  Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, et al. Treatment of chronic Chagas’ disease with itraconazole and allopurinol. Am J Trop Med Hyg. 1998;59(1):133-8.
• ²⁵
  Molina I, Gómez i Prat J, Salvador F, Treviño B, Sulleiro E, Serre N, et al. Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas’ Disease. N Engl J Med. 2014;370(20):1899-908.
• ²⁶
  Torrico F, Gascon J, Ortiz L, Alonso-Vega C, Pinazo MJ, Schijman A, et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect Dis. 2018;18(4):419-30.
• ²⁷
  Nocua-Báez LC, Uribe-Jerez P, Tarazona-Guaranga L, Robles R, Cortés JA, Alberto J, et al. Azoles de antes y ahora: una revisión Azoles of then and now: a review. Rev Chilena Infectol. 2020;37(3):219-30.
• ²⁸
  De Almeida EA, Silva EL, Guariento ME, Aoki FH, De Pedro RJ. Aetiological treatment with itraconazole or ketoconazole in individuals with Trypanosoma cruzi/HIV co-infection. Ann Trop Med Parasitol. 2009;103(6):471-6.
• ²⁹
  Moreira AAB, De Souza HBWT, Amato Neto V, Matsubara L, Pinto PLS, Tolezano JE, et al. Evaluation of the therapeutic activity of itraconazole in human and experimental chronic infection by Trypanosoma cruzi Rev Inst Med Trop Sao Paulo. 1992; 34(2):177-80.
• ³⁰
  Apt W, Arribada A, Zulantay I, Sanchez G, Vargas SL, Rodriguez J. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: The regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. Ann Trop Med Parasitol. 2003;97(1):23-9.
• ³¹
  Pinazo MJ, Espinosa G, Gállego M, López-Chejade PL, Urbina JA, Gascón J. Case report: Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. Am J Trop Med Hyg. 2010;82(4):583-7.
• ³²
  Morillo CA, Waskin H, Sosa-Estani S, del Carmen Bangher M, Cuneo C, Milesi R, et al. Benznidazole and Posaconazole in Eliminating Parasites in AsymptomaticT. cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol. 2017;69(8):939-47.
• ³³
  Torrico F, Gascón J, Barreira F, Blum B, Almeida IC, Alonso-Vega C, et al. New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial. Lancet Infect Dis. 2021;21(8):1129-40.
• ³⁴
  Sousa SMR, Teixeira RR, Costa AV, De Aguiar AR, Fonseca V da R, Lacerda Júnior V, et al. Síntese de novos 1,2,3-triazóis inspirados no SRPIN340 e avaliação de seus efeitos em linhagem celular de glioblastoma humano. Quim Nova. 2021;44(10):1268-79.
• ³⁵
  Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: Current developments. Bioorg Chem.2017;71: 30-54.
• ³⁶
  Bozorov K, Zhao J, Aisa HA. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview. Bioorg Med Chem. 2019;27(16):3511-31
• ³⁷
  Zhang B. Comprehensive review on the anti-bacterial activity of 1,2,3-triazole hybrids. Eur J Med Chem. 2019;168:357-72.
• ³⁸
  Razzaghi-Asl N, Sepehri S, Ebadi A, Karami P, Nejatkhah N, Johari-Ahar M. Insights into the current status of privileged N-heterocycles as antileishmanial agents. Mol Divers. 2020;24(2):525-69
• ³⁹
  Orlando LMR, Lara L da S, Lechuga GC, Rodrigues GC, Pandoli OG, de Sá DS, et al. Antitrypanosomal Activity of 1,2,3-Triazole-Based Hybrids Evaluated Using In Vitro Preclinical Translational Models. Biology. 2023;12(9):1222.
• ⁴⁰
  Leite DI, Fontes F de V, Bastos MM, Hoelz LVB, Bianco M da CAD, de Oliveira AP, et al. New 1,2,3-triazole-based analogues of benznidazole for use against Trypanosoma cruzi infection: In vitro and in vivo evaluations. Chem Biol Drug Des. 2018;92(3):1670-82.
• ⁴¹
  Reis RCFM, dos Santos EG, Benedetti MD, Reis ACC, Brandão GC, Silva GN da, et al. Design and synthesis of new 1,2,3-triazoles derived from eugenol and analogues with in vitro and in vivo activity against Trypanosoma cruzi Eur J Med Chem. 2023;258:115622.
• ⁴²
  Chipoline IC, Brasil BFAB, Neto JSS, Valli M, Krogh R, Cenci AR, et al. Synthesis and investigation of the trypanocidal potential of novel 1,2,3-triazole-selenide hybrids. Eur J Med Chem. 2022;243:114687.
• ⁴³
  Buckner FS, Verlinde CLMJ, Flamme AC La, Van Voorhis WC. Efficient Technique for Screening Drugs for Activity against Trypanosoma cruzi Using Parasites Expressing-Galactosidase. Antimicrob Agents Chemother. 1996;40(11):2592-7.
• ⁴⁴
  Romanha AJ, de Castro SL, Soeiro M de NC, Lannes-Vieira J, Ribeiro I, Talvani A, et al. In vitro and in vivo experimental models for drug screening and development for Chagas disease. Mem Inst Oswaldo Cruz. 2010;105(2):233-8.
• ⁴⁵
  Huber W, Koella JC. A comparison of three methods of estimating ECs0 in studies of drug resistance of malaria parasites. Acta Trop.1993;55(4):257-61.
• ⁴⁶
  Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi Rev Inst Med Trop Sao Paulo. 1962;4:389-96.
• ⁴⁷
  Veloso VM, Carneiro CM, Toledo MJO, Lana M, Chiari E, Tafuri WL, et al. Variation in Susceptibility to Benznidazole in Isolates Derived from Trypanosoma cruzi Parental Strains. Mem Inst Oswaldo Cruz. 2001;96(7): 1005-1011.
• ⁴⁸
  Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg. 1987;81:755-9.
• ⁴⁹
  Kratz JM. Drug discovery for chagas disease: A viewpoint. Acta Tropica. 2019;198:105107.
• ⁵⁰
  Pérez-Molina JA, Molina I. Chagas disease. The Lancet. 2018;391:10115.
• ⁵¹
  Bern C, Kjos S, Yabsley MJ, Montgomery SP. Trypanosoma cruzi and chagas’ disease in the united states. Clin Microbiol Rev. 2011;24(4):655-81.
• ⁵²
  Dias JC, Schofield CJ. Social and Medical aspects on Chagas disease management. In: Telleria J, Tibayrenc M, editors. American Trypanosomiasis: Chagas disease - One hundred years of research. 2nd ed. Oxford: Elselvier; 2017. p. 47-55.
• ⁵³
  Metze K, Lorand-Metze I, De Almeida EA, De Moraes SL. Reactivation of Chagas’ myocarditis during therapy of Hodgkin’s disease. Trop Geogr Med. 1991;43(1):228-30.
• ⁵⁴
  Urbina JA. Chemotherapy of Chagas disease. Curr Pharm Des. 2002;8(4):287-95.
• ⁵⁵
  Urbina JA. Rational Approaches to Specific Chemotherapy of Chagas Disease. In: Tyler KM, Milers MA, editors. World Class Parasites. 7th ed. Boston: Springer; 2003. p. 127-35.
• ⁵⁶
  Apt W, Arribada A, Zulantay I, Rodríguez J, Saavedra M, Muñoz A. Treatment of Chagas’ disease with itraconazole: Electrocardiographic and parasitological conditions after 20 years of follow-up. J Antimicrob Chemother. 2013;68(9):2164-69.
• ⁵⁷
  Brener Z, Cançado JR, Galvão LM, da Luz ZM, Filardi LS, Pereira ME, et al. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz. 1993;88(1):149-53.
• ⁵⁸
  Lauria-Pires L, Castro CN de, Emanuel A, Prata A. Ineficácia do allopurinol em pacientes na fase aguda da doença de Chagas. Rev Soc Bras Med Trop. 1988;21(2):79.
• ⁵⁹
  Berger BJ, Fairlamb AH. Interactions between immunity and chemotherapy in the treatment of the trypanosomiases and leishmaniases. Parasitology. 1992;105 Suppl(S1):S71-8.
• ⁶⁰
  Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MMG, et al. The revised Trypanosoma cruzi subspecific nomenclature: Rationale, epidemiological relevance and research applications. Infect Genet Evol. 2012;12(2):240-53.
• ⁶¹
  Zingales B, Miles MA, Moraes CB, Luquetti A, Guhl F, Schijman AG, et al. Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity. Mem Inst Oswaldo Cruz. 2014;109(6):828-33.
• ⁶²
  Sales Júnior PA, Rezende Júnior CO, Le Hyaric M, de Almeida MV, Romanha AJ. The in vitro activity of fatty diamines and amino alcohols against mixed amastigote and trypomastigote Trypanosoma cruzi forms. Mem Inst Oswaldo Cruz. 2014;109(3):362-4.
• ⁶³
  Gulin JEN, Rocco DM, García-Bournissen F. Quality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic Review. PLoS Negl Trop Dis. 2015;9(11):1-17.

• Financial Support: This work was financed by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) processes APQ-00940-18 and APQ-02576-18.

Publication Dates

• Publication in this collection
  29 July 2024
• Date of issue
  2024

History

• Received
  17 Dec 2023
• Accepted
  09 May 2024